CM
PBYI icon

Caption Management’s Puma Biotechnology PBYI Stock Holding History

Caption Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-25,550
Closed -$1.51M – 618
2018
Q2 		$1.51M Buy
+25,550
New +$1.48M 0.12% 202

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caption Management's PBYI Position: Q3 2018 in Review

Caption Management sold out of Puma Biotechnology (PBYI) in Q3 2018, closing a stake of 25,550 shares — an estimated $1.51M sold.

Caption Management first reported a position in PBYI in Q2 2018 and held it in 1 quarter. The position peaked at $1.51M in Q2 2018. 156 funds tracked by Wall St. Rank hold PBYI as of Q3 2018.

  • Caption Management reported no remaining Puma Biotechnology position as of Q3 2018 after selling out during the quarter.
  • Caption Management sold 25,550 Puma Biotechnology shares in Q3 2018, an estimated $1.51M.
  • Caption Management first reported a position in Puma Biotechnology in Q2 2018 and held it in 1 quarter.
  • Caption Management's Puma Biotechnology position peaked at $1.51M in Q2 2018.
  • 156 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2018.

Based on Caption Management's 13F filing for Q3 2018, filed 14 Nov 2018.